Unique ID issued by UMIN | UMIN000049468 |
---|---|
Receipt number | R000056327 |
Scientific Title | Comparison of medication persistence, adherence, and glycemic control among different administration frequencies for DPP-4 inhibitor in patients with type 2 diabetes: A retrospective cohort study of real-world data |
Date of disclosure of the study information | 2022/11/09 |
Last modified on | 2024/05/13 09:47:08 |
Comparison of medication persistence, adherence, and glycemic control among different administration frequencies for DPP-4 inhibitor in patients with type 2 diabetes: A retrospective cohort study of real-world data
Comparison of medication persistence, adherence, and glycemic control among different administration frequencies for DPP-4 inhibitor in patients with type 2 diabetes
Comparison of medication persistence, adherence, and glycemic control among different administration frequencies for DPP-4 inhibitor in patients with type 2 diabetes: A retrospective cohort study of real-world data
Comparison of medication persistence, adherence, and glycemic control among different administration frequencies for DPP-4 inhibitor in patients with type 2 diabetes
Japan |
Type 2 diabetes mellitus
Medicine in general | Endocrinology and Metabolism |
Others
NO
To examine medication persistence and adherence among different administration frequencies for DPP-4 inhibitor in patients with type 2 diabetes in real-world settings
To examine glycemic control status among different administration frequencies for DPP-4 inhibitors
Others
Actual clinical practice
Others
Others
Not applicable
1. Medication persistence (the duration of time from initiation to discontinuation of therapy, the probability of medication persistence)
2. Medication adherence
Glycemic control
Observational
18 | years-old | <= |
Not applicable |
Male and Female
1. Patients with type 2 diabetes who were prescribed DPP-4 inhibitors during the enrollment period (December 2016 - February 2019)
2. Patients who were prescribed DPP-4 inhibitor monotherapy on an outpatient basis from a single institution under the definition of type 2 diabetes on the index date (the date when prescription of DPP-4 inhibitors was started during the enrollment period)
3. Patients who had been consecutively registered in the database for at least 1 year before the index date (baseline period)
4. Patients who have been consecutively registered in the database for 1 year after the index date (follow-up period)
5. Patients over the age of 18 in the index month
1. Patients who were designated as having type 1 diabetes during the baseline period
2. Patients who had been prescribed DPP-4 inhibitors (single drug or combination drug) during the baseline period
50000
1st name | Hiroyuki |
Middle name | |
Last name | Sugiyama |
Teijin Pharma Limited
Medical Science Department
100-8585
2-1, Kasumigaseki 3-chome, Chiyoda-ku, Tokyo
03-3506-4140
tpm-com@umin.ac.jp
1st name | Tetsuya |
Middle name | |
Last name | Miwa |
Teijin Pharma Limited
Medical Science Department
100-8585
2-1, Kasumigaseki 3-chome, Chiyoda-ku, Tokyo
03-3506-4140
tpm-com@umin.ac.jp
Teijin Pharma Limited
None
Self funding
Teijin Pharma Limited
2-1, Kasumigaseki 3-chome, Chiyoda-ku, Tokyo
03-3506-4140
tpm-com@umin.ac.jp
NO
2022 | Year | 11 | Month | 09 | Day |
Unpublished
Completed
2022 | Year | 10 | Month | 31 | Day |
2022 | Year | 10 | Month | 31 | Day |
2022 | Year | 11 | Month | 09 | Day |
2023 | Year | 01 | Month | 31 | Day |
This is a longitudinal study using the DeSC Database.
2022 | Year | 11 | Month | 09 | Day |
2024 | Year | 05 | Month | 13 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000056327